TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00281580
Drug: Telmisartan 40 mg
Normalized name: telmisartan 40 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 40 mg once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 10 mg
Normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10 mg once daily for six weeks
Study: NCT00281580
Drug: Telmisartan 80 mg
Normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80 mg once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 5 mg
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5g once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 5 mg
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 5 mg
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5mg once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 2.5 mg
Normalized name: amlodipine 2.5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg once daily for eight weeks
Study: NCT00281580
Drug: Amlodipine 5 mg
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5g once daily for two weeks
Study: NCT02520947
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: volatile agent for maintenance of anesthesia
Study: NCT01694186
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00026403
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00026403
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005684
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03574779
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Study: NCT03574779
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
Study: NCT03574779
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
Study: NCT02065804
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection, once, 5 min
Study: NCT00671502
Drug: Carisoprodol SR
Normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 700 mg twice daily
Study: NCT00671502
Drug: Carisoprodol SR
Normalized name: Carisoprodol
DrugBank: Carisoprodol (DB00395)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice daily
Study: NCT03725059
Drug: Paclitaxel (X)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion QW
Study: NCT03725059
Drug: Epirubicin (E)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion either in Q2W or Q3W
Study: NCT02662907
Drug: Barium
Normalized name: barium
DrugBank: Barium sulfate (DB11150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
Study: NCT01168531
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin: 300 mg/day, po, from operative day until third postoperative day.
Study: NCT01168531
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 16 mg, intravenous, before induction of anesthesia
Study: NCT03162536
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
Study: NCT00191152
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
Study: NCT00191152
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression
Study: NCT02358395
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily (800 mg total daily dose).
Study: NCT00581789
Drug: erlotinib, sunitinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
Study: NCT00806026
Drug: placebo and pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
Study: NCT00806026
Drug: pramipexol
Normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Study: NCT00806026
Drug: pramipexol
Normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Study: NCT00806026
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study: NCT00806026
Drug: pramipexol
Normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study: NCT00806026
Drug: pramipexol
Normalized name: Pramipexol
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Study: NCT00047268
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01935154
Drug: Vx-001
Normalized name: BVX-001
DrugBank: BVX-001 (DB18733)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01210443
Drug: Sitaxentan
Normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxentan sodium 100 mg
Study: NCT00976300
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Study: NCT00083109
Drug: Suramin
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00083707
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084279
Drug: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
Study: NCT00552500
Drug: Depakote (valproate)
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg -2000 mg QD based on individual tolerance and VPA levels
Study: NCT00117000
Drug: testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03193307
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 18 \& 29 (Treatment Period)
Study: NCT01370642
Drug: vaniprevir
Normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Study: NCT01370642
Drug: Placebo to vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
Study: NCT01370642
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Study: NCT02234986
Drug: ENMD-2076
Normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral dose, QD for 28 day cycles
Study: NCT02846428
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
Study: NCT02846428
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
Study: NCT02846428
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
Study: NCT02031731
Drug: 4 mg/kg Onartuzumab (MetMAb)
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
Study: NCT02031731
Drug: 15 mg/kg Onartuzumab (MetMAb)
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
Study: NCT02774278
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
Study: NCT01321645
Drug: Azadirachta Indica
Normalized name: Azadirachta indica leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
Study: NCT00408447
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 4 mg/kg/d x 4d
Study: NCT00408447
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2/d x 6d
Study: NCT00408447
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
Study: NCT03580187
Drug: Morphine (+)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization
Study: NCT02273466
Drug: Crobenetine infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01101555
Drug: subcutanious administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
Study: NCT01909401
Drug: boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03093168
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose: 25mg/m2/d
Study: NCT00408915
Drug: Continuous Subcutaneous Lisuride Infusion
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03020082
Drug: Danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
Study: NCT03020082
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir administered orally 100mg BID for 12 weeks;
Study: NCT03020082
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
Study: NCT03020082
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
Study: NCT00063232
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
Study: NCT00190892
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00190892
Drug: carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02644811
Drug: Local anesthesia (buccal and palatal)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
Study: NCT02644811
Drug: Local anesthesia (buccal)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
Study: NCT02268851
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
Study: NCT00093223
Drug: Paclitaxel Nanoparticle Albumin Bound
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
Study: NCT00093223
Drug: Paclitaxel Nanoparticle Albumin Bound
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00093223
Drug: Paclitaxel Nanoparticle Albumin Bound
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 35mg/35 infusion time is 3.5 minutes
Study: NCT02370693
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
Study: NCT02370693
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
Study: NCT02595554
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
Study: NCT02595554
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
Study: NCT02403778
Drug: VESANOID
Normalized name: Vesanoid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
Study: NCT02403778
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is current standard of care treatment for melanoma.
Study: NCT02922660
Drug: desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
Study: NCT02922660
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
Study: NCT03599466
Drug: BF-Lisinopril Tablets 20mg
Normalized name: lisinopril Oral Tablet
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study: NCT01864096
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
Study: NCT04536532
Drug: entecavir tablets
Normalized name: Entecavir Tablets
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
Study: NCT04063904
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 200 mg pill (oral)
Study: NCT04063904
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 400 mcg pills (sublingual)
Study: NCT04303403
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken orally once daily
Study: NCT04303403
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally twice daily
Study: NCT01275937
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
Study: NCT01275937
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
Study: NCT03879577
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered to all patients for a minimum of 4 cycles for 12 weeks.
Study: NCT03879577
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
Study: NCT02031731
Drug: 30 mg/kg Onartuzumab (MetMAb)
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.